Abstract IA004: TEAL: Trial of Exercise And Lifestyle in women with ovarian cancer – improving treatment tolerance through lifestyle medicine

Women with ovarian cancer often experience treatment-related toxicities, functional decline, and diminished quality of life during chemotherapy. Exercise and lifestyle interventions may mitigate these effects, but few randomized trials have evaluated their impact on chemotherapy delivery. The Trial of Exercise And Lifestyle (TEAL) in women with ovarian cancer, part of the NCI’s Exercise and Nutrition Interventions to Improve Cancer Treatment-Related Outcomes (ENICTO) consortium, tests whether structured exercise and nutrition improve treatment tolerance, measured by relative dose intensity (RDI), while enhancing functional and patient-reported outcomes. TEAL is a randomized controlled trial enrolling women newly diagnosed with ovarian cancer undergoing chemotherapy. Participants are randomized 1:1 to an 18-week supervised intervention (aerobic and resistance training plus individualized nutrition counseling with digital health monitoring) or standard of care. The primary outcome is chemotherapy RDI; secondary outcomes include patient-reported toxicities and body composition, with exploratory analyses of digital biomarkers from wearable devices. To date, 60 of 200 women have enrolled, with over half opting to participate in Spanish. Early results demonstrate strong recruitment, good adherence to intervention sessions, and high participant engagement, though uptake of wearable monitoring and D3 creatine body composition measures has varied. TEAL is among the first randomized trials to test whether lifestyle interventions can improve chemotherapy receipt in ovarian cancer. Preliminary findings support feasibility, strong participant engagement, and offer a novel framework for integrating lifestyle medicine and digital health into supportive oncology with potential to inform survivorship guidelines and future multi-site trials. Citation Format: Tracy E. Crane. TEAL: Trial of Exercise And Lifestyle in women with ovarian cancer – improving treatment tolerance through lifestyle medicine [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Ovarian Cancer Research; 2025 Sep 19-21; Denver, CO. Philadelphia (PA): AACR; Cancer Res 2025;85(18_Suppl):Abstract nr IA004.